JX-2105
- Generic Name
- JX-2105
A Randomized, Double-blind, Placebo-controlled Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JX2105 in Healthy Chinese Subjects
- First Posted Date
- 2024-08-05
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Zhejiang Jingxin Pharmaceutical Co., Ltd.
- Target Recruit Count
- 52
- Registration Number
- NCT06537050
- Locations
- 🇨🇳
Beijing Ditan Hospital, Capital Medical University, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath